ImageneBio, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters is located in San Diego, California. As of December 31, 2025, we lease approximately 2,596 square feet of office space in San Diego, California, which houses research and development and certain administrative functions, and pay an aggregate of approximately $17,000 in rent per month.
We have a second lease agreement for 28,029 square feet of office and laboratory space in San Francisco, California (the “San Francisco Lease”) as a result of the acquisition of Pionyr Immunotherapeutics, Inc. on August 4, 2023. The San Francisco Lease is currently subleased by third parties and is expected to expire on April 30, 2027.
We believe that our existing facilities will meet our current and near-term needs, and that suitable additional space will be available as and when needed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.